Investor's Business Daily on MSN
Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat
Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older ...
TipRanks on MSN
Vertex price target lowered to $32 from $42 at Piper Sandler
Piper Sandler analyst Brent Bracelin lowered the firm’s price target on Vertex (VERX) to $32 from $42 and keeps an Overweight rating on the ...
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...
Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback